<DOC>
	<DOCNO>NCT00907140</DOCNO>
	<brief_summary>Rationale : Diagnostic procedure , positron emission tomography ( PET ) use fluorodeoxyglucose ( FDG ) , may help determine response standard cancer therapy patient cervical cancer The purpose study evaluate change cervical tumor heterogenity measure FDG-PET/CT imaging .</brief_summary>
	<brief_title>Fludeoxyglucose ( FDG ) Positron Emission Tomography/Computed Tomography ( PET/CT ) Cervical Heterogenity Imaging Study</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 . Biopsyproven cervical cancer . ( FIGO stageIb2IVa ) 2 . Age â‰¥ 18 3 . Able receive chemoradiation therapy Cisplatin . 4 . Nonpregnant status woman childbearing potential . 5 . No active cancer time diagnosis cervical cancer Patients receive treatment malignancy , exception nonmelanoma skin cancer , past 5 year . 6 . Patients distant metastatic disease eligible provide estimate survival patient least 1 year . 7 . Scheduled undergo already undergone FDGPET/CT image clinical stag cervical cancer BarnesJewish Hospital Clinical PET Facility Biograph 40 PET/CT scanner 8 . Able give inform consent 1 . Age &lt; 18 2 . Patients know active malignancy cervical carcinoma . 3 . Pregnant breastfeeding patient . 4 . Subjects whose tumor FDG avid baseline standard care FDGPET/CT imaging</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cervical Cancer</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Fluorodeoxyglucose</keyword>
</DOC>